

Phospho-Lyn (Tyr507) (5B6) rabbit mAb

www.abwizbio.com

Support: info@abwizbio.com

Order: sales@abwizbio.com

#2416

Store at: -20°C

For Research Use Only. Not For Use In Diagnostic Procedures.

Applications	Detection	Clonality	Isotype
Flow Cytometry, WB	Anti-Rabbit IgG	Monoclonal	Rabbit IgGk

Format: Unconjugated

Cross Reactivity: Predicted to work with mouse, rat and other homologues.

Formulation: 1X PBS, 0.02% NaN₃, 50% Glycerol, 0.1% BSA

Preparation: Protein A+G

Reactivity: Human, Mouse

Recommended


Usage: 1µg/mL ? 0.001µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.

Immunogen: A synthetic phospho-peptide corresponding to residues surrounding Tyr507 of human phospho Lyn


Description: Lyn, along with Btk, supports the abnormal growth and survival of neoplastic mast cells. Phosphorylated Lyn has been identified in these cancerous cells, along with phosphorylated Btk, Hck, and Stat5. Dasatinib, a chemotherapy drug used to treat leukemia, is a tyrosine kinase inhibitor that binds directly to Lyn in neoplastic cells. Lyn and Btk have also been shown to be involved in IgE receptor-dependent activation. Increased Lyn activity, detected by higher amounts of phospho Lyn, has been demonstrated in breast cancer cell lines. This is likely mediated through effects of upstream regulators of Lyn, rather than mutations in Lyn itself.

References:

Gleixner KV, Mayerhofer M, Cerny-Reiterer S et al. (2011) Blood. 28: 1077-1086.
Choi Y, Bocanegra M, Kwon MJ et al. (2010) Molecular and Cellular Pathology. 70: 2296-2306.




Flow cytometric analysis of Jurkat cells secondary antibody only negative control (blue) or untreated (red) or treated with IFN γ + IL-4 + pervanadate (green) using Phospho-Lyn (Tyr507) antibody LynY507-5B6 at 0.01 μ g/mL. Cat. #2416.




Peptide blocking flow cytometric analysis of Jurkat cells secondary antibody only negative control (light blue) or untreated (red) or treated with IFN γ + IL-4 + pervanadate (green) or untreated and blocked with phospho-peptide (black) or treated and blocked with phospho-peptide (gold) or untreated and blocked with non-phospho peptide (dark blue) or treated and blocked with non-phospho peptide (purple) using Phospho-Lyn (Tyr507) antibody LynY507-5B6 at 0.01 μ g/mL. Cat. #2416.


IgG	Treatment	Peptide Block	Median : BL1-A
5B6	IFN γ IL4Pv	Non-Phos.	65561
5B6	Ctrl	Non-Phos.	2851
5B6	IFN γ IL4Pv	Phospho.	231
5B6	Ctrl	Phospho.	217
5B6	IFN γ IL4Pv	-	69140
5B6	Ctrl	-	3169
2' only	Ctrl	-	116




Flow cytometric analysis of C2C12 cells secondary antibody only negative control (blue) or treated with imatinib (red) or with pervanadate (green) using Phospho-Lyn (Tyr507) antibody LynY507-5B6 at 0.01 μ g/mL. Cat. #2416.



Western blot analysis of extracts of HeLa cells treated with H₂O₂. Cell lysates were ran on a SDS-PAGE gel, transferred to nitrocellulose membrane, blocked and non-treated (-) or treated with lambda phosphatase (+) and stained using anti-phosph-Lyn (Tyr507) 5B6 rabbit recombinant antibody #2416.



Western blot analysis of HeLa cell extract, untreated or treated with H₂O₂ using Phospho-LYN(TYR507) antibody LYN507-5B6 at 0.01 ug/mL. Cat. #2416.



Western blot analysis of HeLa cell extract, untreated or treated with H₂O₂ using 0.01 µg/mL Phospho-Lyn (Tyr507) antibody LynY507-5B6 Cat. #2416 or Company A antibody at 1 µg/mL (manufacturer's recommended concentration) developed using the same exposure.